Current Report Filing (8-k)
November 18 2020 - 9:30AM
Edgar (US Regulatory)
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): November 17, 2020
AKERS
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
|
New
Jersey
|
|
001-36268
|
|
22-2983783
|
|
(State
or other jurisdiction of
|
|
(Commission
|
|
(I.R.S.
Employer
|
|
incorporation
or organization)
|
|
File
Number)
|
|
Identification
Number)
|
201
Grove Road
Thorofare,
New Jersey USA 08086
(Address
of principal executive offices, including zip code)
(856)
848-8698
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under
any of the following provisions:
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
|
Common
Stock, no par value
|
|
AKER
|
|
The
NASDAQ Capital Market
|
Item
8.01 Other Events.
On
November 17, 2020, Akers Biosciences, Inc. (the “Company”) closed a previously announced private placement of 9,765,933
shares of its common stock and warrants to purchase 9,765,933 shares of its common stock resulting in aggregate gross proceeds
to the Company of approximately $18.1 million (the “Private Placement”). In connection with the Private Placement
and pursuant to a previously reported engagement letter entered into by and among the Company and Katalyst Securities LLC (the
“Placement Agent”), the Company also issued the Placement Agent a warrant to purchase up to 390,368 shares of the
Company’s common stock at an exercise price of $1.85 (the “Placement Agent Warrant”). The Placement Agent Warrant
will be exercisable at any time and from time to time, in whole or in part, following the date of issuance and for a term of five
and a half years.
A
form of the Placement Agent Warrant is attached hereto as Exhibit 4.1 and is incorporated herein by reference. The description
of the Placement Agent Warrant herein does not purport to be complete and is qualified in its entirety by reference to Exhibit
4.1.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
AKERS
BIOSCIENCES, INC.
|
|
|
|
|
Dated:
November 18, 2020
|
/s/
Christopher C. Schreiber
|
|
|
Christopher
C. Schreiber
|
|
|
Executive
Chairman and President
|
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Apr 2023 to Apr 2024
